ImClone Systems Starts Solid Malignancies & Lymphoma Trial Enrollment (IMCL)

June 25, 2008 · Filed Under Cancer 

ImClone Systems Inc. (NASDAQ: IMCL) has announced that its Phase 1 clinical trial of IMC-A12, itss fully human IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody plus the mTOR inhibitor temsirolimus, has opened for enrollment in patients with advanced solid malignancies and lymphoma.

This study is being carried out at the M.D. Anderson Cancer Center in Houston, Texas and the Barbara Anne Karmanos Cancer Institute/Wayne State University in Detroit, Michigan.  This study is a component of an initial stage of at least 10 Phase 1 and 2 clinical trials of IMC-A12.  It is designed to specifically target the human IGF-1R to block a signaling pathway that enhances tumor cell proliferation and survival.

In 2007, ImClone completed enrollment into two Phase 1 studies of IMC-A12 with favorable safety and pharmacokinetic profiles, as well as preliminary evidence of anti-tumor activity as a single agent when administered either weekly or every two weeks.

In addition to this Phase 1 study of IMC-A12 plus temsirolimus, Phase 2 studies of IMC-A12 in patients with advanced prostate, pancreatic, colorectal, liver, and head and neck cancers, as well as a series of Phase 1/2 studies in pediatric malignancies, have begun to enroll patients.

Jon Ogg
June 25, 2008

Tags: , , ,

Comments

Comments are closed.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed